PatientsVille.com Logo

FLUSHING and ZOCOR

PatientsVille

FLUSHING Symptoms and Causes

Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute

Check out the latest treatments for FLUSHING

FLUSHING treatment research studies

ZOCOR clinical trials, surveys and public health registries


Find Drug Side Effect reports



ZOCOR Side Effects

Rhabdomyolysis (1045)
Myalgia (844)
Blood Creatine Phosphokinase Increased (494)
Asthenia (430)
Muscular Weakness (393)
Renal Failure Acute (366)
Pain In Extremity (328)
Arthralgia (302)
Muscle Spasms (284)
Fatigue (263)
Myopathy (253)
Renal Failure (231)
Pain (228)
Dyspnoea (220)
Myocardial Infarction (202)
Myositis (201)
Nausea (196)
Alanine Aminotransferase Increased (184)
Chest Pain (179)
Dizziness (178)
Fall (128)
Aspartate Aminotransferase Increased (127)
Malaise (122)
Cerebrovascular Accident (120)
Diarrhoea (119)
Headache (104)
Back Pain (101)
Liver Function Test Abnormal (101)
Depression (100)
Abdominal Pain (95)
Gait Disturbance (93)
Blood Creatinine Increased (93)
Anxiety (92)
Abasia (91)
Vomiting (87)
Amnesia (86)
Abdominal Pain Upper (79)
Anaemia (78)
Coronary Artery Disease (76)
Insomnia (75)
Cardiac Failure Congestive (74)
Weight Decreased (73)
Dehydration (72)
Pyrexia (71)
Confusional State (70)
Paraesthesia (70)
Hypertension (69)
Pneumonia (69)
Rash (68)
Cardiac Disorder (67)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

How long does it take to get back to normal after taking Zocor. I had a major problem in November 2008 and it is now May 2009 and I am still having problems and testing. It has cost me a fortune and they still say it is not Zocor but I still believe

I am asking, does Levaxin a thyroid med. and Zantac antiacid, is it OK to take those at the same time

I have a frozen diagfram and shrinking lung. It affects my breathing and energy. Could this possibly be caused by Zocor as I was told by someone who also has this condition. I also have lots of muscle pain daily.&nbs

Lip swelling, acute.

Urinary retention Is there a correlation between this and using a statin. Had this problem shortly after starting a simvistatin routine.

Zocor 40 mg, Typical gout experience 2 times a month, treatable with fluids and diet. Some use of colchicine. Within a week of using Zocor experienced gout over an extended period of time. Basically 6 weeks straight. Taking Zocor at night and exp

Zocor 40mg. Since I started taking have had rotator repair, frozen shoulder same shoulder, tarsal tunnel in my ankle. Surgery and now frozen shoulder other shoulder that my doc wants to operate on

After the first treatment I had some eye dryness and flushing both of which were not bad. After the second treatment I have very dry eyes and blured vision. The flushing with the second treatment has been unbearable. I h

Do Not Take This Medication. I am a physician who had surgery and prescribed for post op pain. Horrible Side Effects.Horrible Dizziness, Rash, Flushing, which lasted an extended period of time. I will not prescribe this medication to a patient and

Facial flushing and heaviness of the eyes

Flushing chest pain itchy joint pain sleeplessness memory loss short term mood swings depression

Flushing of cheeks, neck area after taking 50mg for pain associated with breast reconstruction

Horrible antibiotic taste in my mouth!! Its like the antibiotics have not down / having a reflux. Flushing down with water to lessen bitter pill taste in my mouth , not really helpingHave h-pylori and on 7 day course. Can't wait to finish this awfu

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I forgot to mention - my blood pressure during this mornings' flushing/SVT episode was 180/112. This morning before I took the Sular (with 12.5mg lopressor) it was 128/88. I almost didnt take the Sular but decided not to treat myself then ask the d

I have been taking Requip for at least 5-6 yrs now for RLS.Biggest mistake I ever made.Every time I try to stop it it is horrible!I have severe flushing of my face,my BP gets high,nauseated, my RLS gets worse,can't sleep etcThe emotional turmoill i

Remicade treatments in 2003 for Crohn's disease. During administration of my third dose, I immediately experienced severe chest pain, flushing, increased heart rate, and vomitting. In 2004, an abdominal CT was clear. In 2007, I was diagnosed with n

FLUSHING Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Benefit of Follicular Flushing During Oocyte Retrieval for Poor Responder Patient in an Assisted Reproductive Technology Program
Conditions: Infertility, Female;   Ovarian Insufficiency
Intervention: Procedure: Direct aspiration needle Echo tip® Cook® single Lumen and Follicular Flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration
Outcome Measures: the number of mature oocytes collected;   quality of embryos obtained;   Number of embryos obtained;   Number of transferable embryos (transferred and frozen);   Number of pregnancies obtained
2 Not yet recruiting Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate (DMF)-Treated Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Drug: Acetylsalicylic acid;   Drug: ASA-Placebo
Outcome Measures: Incidence of Participant-Reported Flushing Events During the First 4 Weeks Treatment;   Severity of Participant-Reported Flushing Events During the First 4 Weeks of Treatment based on the MGFSS and MFSS data;   Incidence of Participant-Reported Flushing Events During Weeks 5-8 and Weeks 9-12 of the study using MGFSS and MFSS data;   Severity of Participant-Reported Flushing Events During Weeks 5-8 and Weeks 9-12 of the study using MGFSS and MFSS data;   Duration of Participant-Reported Flushing Events During Weeks 1-4, 5-8 and 9-12 of the study using MGFSS and MFSS data;   Incidence of Participant-Reported Flushing Events During Weeks 13-48 of Treatment;   Incidence of Treatment Discontinuation and Study Withdrawal Due to Any Adverse Event;   Incidence of Treatment Discontinuation and Study Withdrawal Due to Flushing Events;   Incidence of Treatment-emergent Adverse Events;   Incidence of Serious Adverse Events (SAEs);   Change from Baseline to Week 24 and Week 48 in Quality of Life Measurements as Assessed by the Short Form 36 (SF-36) and European Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L) Questionnaires
3 Recruiting Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.
Condition: Complication of Catheter
Intervention: Other: Reduced port-flush schedule
Outcome Measures: Time to port complication;   Frequency and severity of toxicity;   Cost effectiveness
4 Recruiting Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children
Conditions: Infection of Intravenous Catheter;   Phlebitis;   Extravasation of Diagnostic and Therapeutic Materials
Interventions: Drug: 0,9% NaCl flush;   Drug: Heparin 50U/ml
Outcome Measures: Average length of stay on site of the catheter measured in hours;   Incidence of complications extimated overall and by type of complication;   Average cost for the maintenance of the catheter of each subject (pro day and in total)
5 Recruiting Treatment of Abdominal Abscesses With or Without Fibrinolysis
Conditions: Abdominal Abscess;   Tissue Plasminogen Activator
Interventions: Procedure: Tissue plasminogen activator abscess flush;   Procedure: Saline flush of abscess
Outcome Measure: Length of hospital stay
6 Recruiting Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Condition: Menopausal Hot Flushes
Intervention: Drug: Sage extract, 3400 mg , DER 1:17
Outcome Measures: Change from Baseline Hyperhidrosis Disease Severity Scale;   Change from Baseline Menopause Rating Scale / MRS;   Change from Baseline Modified Dem Tect
7 Recruiting Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Conditions: Early Allograft Dysfunction;   Ischemic Reperfusion Injury;   Liver Transplantation;   Hyperfibrinolysis
Intervention: Drug: Tacrolimus
Outcome Measures: early allograft dysfunction;   ischemic reperfusion injury of the liver allograft;   inflammatory response to reperfusion;   Postreperfusion hyperfibrinolysis
8 Recruiting Safety and Efficacy of Dr. Tagliaferri's Menopause Formula
Condition: Hot Flashes
Intervention: Dietary Supplement: Dr. Tagliaferri's Menopause Formula
Outcome Measures: Change in frequency of moderate to severe hot flushes from baseline to 12 weeks.;   Adverse events assessment;   Change in the frequency of hot flushes that awake participants during sleep;   Change in frequency of moderate to severe hot flushes from baseline to week 4;   Change in severity of moderate to severe hot flushes from baseline to week 4;   Change in severity of moderate to severe hot flushes from baseline to week 12;   The clinical meaningfulness of the reduction in hot flashes;   Change in weight and body mass index (BMI) from baseline compared to study termination;   change in blood pressure from baseline compared to study termination.;   Adherence to study medication based on pill counts
9 Unknown  "Pi" and Hot Flushes
Condition: Menopausal Symptom Relief
Interventions: Drug: Capsicum frutescens fruits, homeopathic medicine;   Drug: Inert alcoholic solution
Outcome Measures: MYMOP (Measure Yourself Medical Outcome Profile);   ORIDL (Outcome Related to Impact on Daily Living)
10 Recruiting Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms
Conditions: Hot Flushes;   Night Sweats
Interventions: Drug: Oral micronized progesterone;   Drug: placebo
Outcome Measures: Vasomotor Symptoms (VMS)/ VMS Score;   Frequency of VMS;   Severity of VMS;   Sleep problems;   Mood;   Health-related Quality of Life
11 Recruiting The Topical Niacin Skin Flush Test in First Episode Psychosis
Conditions: Psychotic Disorders;   Schizophrenia
Intervention: Other: skin test
Outcome Measure: change in visual rating of skin response (redness and oedema)
12 Unknown  A Study of MF101 in Postmenopausal Women
Conditions: Hot Flushes;   Vasomotor Symptoms
Interventions: Drug: MF101 5 g/day;   Drug: Placebo;   Drug: MF101 10 g/day
Outcome Measure: Determine the safety and efficacy of two doses of MF101 (5 g/day and 10 g/day) compared to placebo.
13 Recruiting International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation
Condition: Lung Preservation
Interventions: Device: OCS Lung;   Device: Cold flush and storage
Outcome Measures: Primary study endpoint is a composite of patient and graft survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 at 72 hours post-transplantation.;   Incidence of International Society for Heart & Lung Transplantation (ISHLT) PGD Grade 3 at 72 hours post-transplantation;   Incidence of ISHLT PGD Grade 2 or 3 at 72 hours post-transplantation;   Patient survival at day 30;   Graft survival at day 30
14 Not yet recruiting Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
Condition: Catheter-related Infection
Intervention: Procedure: blood levels
Outcome Measure: comparison of central (via port device) and peripherally obtained vancomycin levels: the difference, when using the new Flushing technique, is allowed to be maximally 0.5 mg/L
15 Unknown  Menopause and Meditation for Breast Cancer Survivors
Condition: Menopause
Intervention: Behavioral: Mindfulness Meditation
Outcome Measures: hot flushes;   Sleep
16 Recruiting Health Effects of Resistance Training on Postmenopausal Women
Conditions: Hot Flashes;   Menopause
Intervention: Other: Resistance training
Outcome Measures: Change in frequency of hot flushes per 24 h;   Health-related quality of life (HRQoL);   Muscle strength;   Level of physical activity;   Concentrations of adipo-myokines/inflammatory biomarkers;   Length of telomeres;   Volume of white and brown adipose tissue and muscle volume;   Body mass index and abdominal height;   Blood pressure;   Severity of hot flushes
17 Not yet recruiting Estromineral Serena Plus and Symptomatic Menopause
Condition: Menopause
Interventions: Dietary Supplement: Estromineral Serena Plus;   Dietary Supplement: Estromineral
Outcome Measures: Kupperman index;   Adverse events
18 Recruiting P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
Outcome Measures: Frequency of Symptoms;   Rate of Progression Free Survival (PFS)
19 Recruiting Qing'E Formula Therapy on Menopausal Symptoms
Condition: Menopause
Interventions: Drug: Qing'E pills;   Drug: Placebo
Outcome Measures: Hot flushes;   Mean differences of Kupperman index;   Mean difference of single clinical symptom in Kupperman index
20 Recruiting Alternative Treatments for Menopausal Women
Conditions: Menopause;   Hot Flushes;   Osteoporosis;   Dyslipidemia
Interventions: Dietary Supplement: Placebo;   Dietary Supplement: Red Clover extract
Outcome Measure: Primary Menopause-related symptoms